PURPOSE: The purpose of this study was to evaluate the results of two sequential total body irradiation (TBI) regimens, especially focusing on pulmonary complications. MATERIALS AND METHODS: Patients with malignant disease who underwent TBI followed by bone marrow transplantation were retrospectively reviewed. There were 86 patients (51 males, 35 females). Altogether, 36 patients were treated on twice-daily fractions of 2 Gy for 3 days to a total 12 Gy (group A). Another 50 patients were treated on once-daily fractions of 2.4 or 3.0 Gy for 4 or 5 days to a total 12 Gy (group B). RESULTS: The 5-year overall survival rate was 49.2%, and relapse-free survival was 44.3%. There were no significant differences between the two groups regarding overall survival (P = 0.1237) or relapse-free survival (P = 0.1548). Two patients in group A had interstitial pneumonitis of grade 3 or higher severity compared with three patients in group B. There was no significant difference between patients in group A (5-year probability rate was 7.6%) and patients in group B (5-year probability rate was 13.9%) (P = 0.9519). CONCLUSION: We concluded that our once-daily TBI regimen is feasible and had the benefit of reducing the complexity of TBI. We believe that further investigation of the TBI regimen is needed.
PURPOSE: The purpose of this study was to evaluate the results of two sequential total body irradiation (TBI) regimens, especially focusing on pulmonary complications. MATERIALS AND METHODS:Patients with malignant disease who underwent TBI followed by bone marrow transplantation were retrospectively reviewed. There were 86 patients (51 males, 35 females). Altogether, 36 patients were treated on twice-daily fractions of 2 Gy for 3 days to a total 12 Gy (group A). Another 50 patients were treated on once-daily fractions of 2.4 or 3.0 Gy for 4 or 5 days to a total 12 Gy (group B). RESULTS: The 5-year overall survival rate was 49.2%, and relapse-free survival was 44.3%. There were no significant differences between the two groups regarding overall survival (P = 0.1237) or relapse-free survival (P = 0.1548). Two patients in group A had interstitial pneumonitis of grade 3 or higher severity compared with three patients in group B. There was no significant difference between patients in group A (5-year probability rate was 7.6%) and patients in group B (5-year probability rate was 13.9%) (P = 0.9519). CONCLUSION: We concluded that our once-daily TBI regimen is feasible and had the benefit of reducing the complexity of TBI. We believe that further investigation of the TBI regimen is needed.
Authors: D Blaise; D Maraninchi; E Archimbaud; J Reiffers; A Devergie; J P Jouet; N Milpied; M Attal; M Michallet; N Ifrah Journal: Blood Date: 1992-05-15 Impact factor: 22.113
Authors: O Ringdén; M Remberger; T Ruutu; J Nikoskelainen; L Volin; L Vindeløv; T Parkkali; S Lenhoff; B Sallerfors; L Mellander; P Ljungman; N Jacobsen Journal: Blood Date: 1999-04-01 Impact factor: 22.113
Authors: R C Tait; A K Burnett; A G Robertson; S McNee; B M Riyami; R Carter; R D Stevenson Journal: Int J Radiat Oncol Biol Phys Date: 1991-06 Impact factor: 7.038
Authors: O Ringdén; T Ruutu; M Remberger; J Nikoskelainen; L Volin; L Vindeløv; T Parkkali; S Lenhoff; B Sallerfors; P Ljungman Journal: Blood Date: 1994-05-01 Impact factor: 22.113
Authors: P Latini; C Aristei; F Aversa; F Checcaglini; E Maranzano; C Raymondi; B M Panizza; E Perrucci; M F Martelli Journal: Radiother Oncol Date: 1991-10 Impact factor: 6.280
Authors: G Socie; A Devergie; T Girinsky; J Reiffers; J P Vernant; J P Le Bourgeois; P Herve; D Guyotat; D Maraninchi; B Rio Journal: Int J Radiat Oncol Biol Phys Date: 1991-03 Impact factor: 7.038
Authors: John Patrick Connors; Patrick Garvin; Jacob Silver; Adam Lindsay; Olga Solovyova Journal: Arch Orthop Trauma Surg Date: 2022-08-19 Impact factor: 2.928
Authors: Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht Journal: Front Pediatr Date: 2021-12-03 Impact factor: 3.418
Authors: Dong-Yun Kim; Il Han Kim; Sung-Soo Yoon; Hyoung Jin Kang; Hee Young Shin; Hyun-Cheol Kang Journal: Radiat Oncol Date: 2018-09-18 Impact factor: 3.481